Yahoo Finance

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ -- Echosens, the leader in non-invasive liver diagnostics, is announcing today that the U.S. Food and Drug Administration's (FDA's) Center for Drug ...
Business Wire

Echosens Introduces FibroScan 630 Expert: Adds New Spleen Stiffness Measurement (SSM by VCTE™) for Risk Stratification of Patients With Advanced Chronic Liver Disease

PARIS--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, announces the launch of FibroScan 630 Expert, a high-performance elastography engine that ...
Business Wire

American Association of Clinical Endocrinology New Clinical Practice Guidelines Recommend VCTE FibroScan ® Technology by Echosens

PARIS & WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan ® portfolio of solutions, is pleased to announce that the “American Association of Clinical ...
Finanznachrichten

Echosens: FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

This milestone opens a path for FibroScan ® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...
manilatimes

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development This is the first time the FDA is ...
PR Newswire

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

This milestone opens a path for FibroScan ® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...